Contents hide 1 About Glumetinib or Gumarontinib 2 Approval 3 Dosage and administration 3.1 Dose adjustment About Glumetinib or Gumarontinib Glumetinib (SCC244) also named Gumarontinib， is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor.Glumetinib has excellent pharmacokinetic characteristics with long half-life and high steady-state trough concentration in human body, which is conducive to the continuous inhibition of the target. Glumetinib sold as brand name 海益坦® in china. Gumarontinib sold as brand name ハイイータン® in Japan. Approval In June 2024, the MET inhibitor Glumetinib tablets were approved for marketing by the Ministry of Health, Labor and Welfare of Japan for the treatment … Continue reading 海益坦 (Glumetinib) ハイイータン